Mortality risk of antipsychotic augmentation for adult depression.

ABSTRACT:

Importance

Randomized controlled trials have demonstrated increased all-cause mortality in elderly patients with dementia treated with newer antipsychotics. It is unknown whether this risk generalizes to non-elderly adults using newer antipsychotics as augmentation treatment for depression.

Objective

This study examined all-cause mortality risk of newer antipsychotic augmentation for adult depression.

Design

Population-based new-user/active comparator cohort study.

Setting

National healthcare claims data from the US Medicaid program from 2001-2010 linked to the National Death Index.

Participants

Non-elderly adults (25-64 years) diagnosed with depression who after ≥3 months of antidepressant monotherapy initiated either augmentation with a newer antipsych

SUBMITTER: Gerhard T 

PROVIDER: S-EPMC7526884 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature